Shilpa Medicare Ltd 2020 AR2
The report highlights Shilpa Medicare Limited's performance for the fiscal year 2019-20, during which the company achieved a consolidated revenue growth of 24% to ₹925 crore and a 39% increase in Profit After Tax to ₹156 crore. SML expanded its oncology API and formulation capabilities, launching key generic drugs like Lenshil and Ibrushil. The company advanced its pipeline with multiple ANDA filings and approvals, while transitioning its biologicals business to a dedicated subsidiary. On the sustainability front, the company achieved zero liquid discharge across its facilities, reduced greenhouse gas emissions by 25,000 tonnes, and invested ₹326 lakhs in corporate social responsibility initiatives.
Company: Shilpa Medicare Ltd
Sector: Manufacturing
Country: India
Year: 2020
Type: AR2
Pages: 249
Back to company
Shilpa Medicare Ltd
Annual Report
The report highlights Shilpa Medicare Limited's performance for the fiscal year 2019-20, during which the company achieved a consolidated revenue growth of 24% to ₹925 crore and a 39% increase in Profit After Tax to ₹156 crore. SML expanded its oncology API and formulation capabilities, launching key generic drugs like Lenshil and Ibrushil. The company advanced its pipeline with multiple ANDA filings and approvals, while transitioning its biologicals business to a dedicated subsidiary. On the sustainability front, the company achieved zero liquid discharge across its facilities, reduced greenhouse gas emissions by 25,000 tonnes, and invested ₹326 lakhs in corporate social responsibility initiatives.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2020
Reporting Period
Apr 1, 2019 - Mar 31, 2020
Fiscal Year
2020
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Employees